Abstract
A library of substituted aryl1,3-oxazole-oxazolo[4,5-b]pyridin-2-yl)benzo[d]thiazol-6-yl)thiazole-2-carboxamides (12a-j) were designed and developed. Further, compounds were investigated towards cervix (SiHa), lung (A549), breast (MCF-7) and colon (Colo-205) human cancer cell lines by employing of MTT assay, and the results compared with clinically utilized therapeutic agent, etoposide. Most of the tested compounds exhibited good to moderate activity as etoposide. Amongst, these compounds 12a, 12b, 12c, 12 h, 12i and 12j possessed more potent activities. Predominantly, one compound 12a displayed superior activity. Molecular docking studies were performed for all synthesized compounds against the potential molecular cancer targets of EGFR and FAK tyrosine kinase enzymes.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
